Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in Patients With Post-herpetic Neuralgia

NCT01848730 is registered in ClinicalTrials.gov with Convergence Pharmaceuticals as lead sponsor.

NCT NCT01848730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01848730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in Patients With Post-herpetic Neuralgia
Lead sponsor
Convergence Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2013
Completion date
May 31, 2014
Enrollment
103 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post-herpetic neuralgia